Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LCTG-001
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Lactiga
Deal Size : Undisclosed
Deal Type : Collaboration
Kenox Partners with Lactiga to Advance Mucosal-Targeted Immunotherapy
Details : The collaboration will leverage Kenox extensive expertise in nasal and inhaled pharmaceutical development of LCTG-001. It is being evaluated for mucosal-targeted Secretory IgA.
Product Name : LCTG-001
Product Type : Antibody
Upfront Cash : Undisclosed
March 10, 2025
Lead Product(s) : LCTG-001
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Lactiga
Deal Size : Undisclosed
Deal Type : Collaboration